---
run_id: halo-evidence-vs-diagnosis-validation-v10-generic-advice-prompted-08
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
model_condition: generic_advice_prompted
run_number: 8
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 805
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
condition_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
output_file: model-outputs/generic_advice_prompted-08.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 08)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v10-v1`, condition `generic_advice_prompted`, run 8 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 805, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### The Reasoning
You are currently facing a "false positive" signal. Your financial metrics (expansion bookings) and surface-level usage (39% increase) are being driven by incentives—bundle pricing for early renewals and managers using the tool for training/oversight—rather than by value creation for the end-user (the adjuster).

The most dangerous signal is the "behavioral cliff": adjusters use DraftPath for two days and then revert to manual notes. In B2B workflow software, this is the classic precursor to churn. The fact that regional carriers are already planning to remove the feature suggests that the "enthusiastic comments" collected by Sales were likely a result of the roadmap pitch (selling the future) rather than the current utility (the present).

The **Usage Quality Sprint** is too lagging; it measures *if* people return, but not *why* they leave. The **Commercial Cleanroom** is too risky; it tests pricing elasticity and sales tactics, but doesn't fix the underlying product deficiency. Scaling broadly right now would be "scaling a leak."

The **Claim File Review** is the only option that attacks the root cause: the gap between a "proposed action" and an "executable/defensible action." By auditing actual files, you will discover if the tool is providing genuine intellectual lift or if it is simply producing "plausible-sounding" suggestions that adjusters find too risky or tedious to defend to their reviewers.

### The Tradeoff
By choosing the Claim File Review, you are displacing the **Commercial Cleanroom**.

**What you give up:** You lose the ability to scientifically determine if DraftPath is actually driving renewal velocity or if you are simply subsidizing renewals with bundle pricing. You will enter next year without knowing the "true" market price of this feature, meaning your revenue forecasts for DraftPath remain speculative and potentially inflated.

### The Strongest Reason Against This Recommendation
The Claim File Review is a qualitative, manual process that produces "small n" data. It does not provide the statistical confidence of a Cleanroom or the real-time monitoring of a Quality Sprint. There is a risk that you spend your limited budget on a deep-dive audit only to find "local" problems in a few files, while the broader issue is actually a pricing or sales-alignment problem that only the Cleanroom would have revealed.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "behavioral cliff" (adjusters reverting to manual notes) was happening *only* in the regulated health-liability segment, while adjusters in all other segments maintained high, autonomous usage rates.

If the product is working for 80% of your users and only failing in one regulated vertical, the problem is a "segment fit" issue rather than a "core value" issue. In that case, the risk shifts from *product failure* to *commercial mispricing*, making the Cleanroom the higher-leverage move.
